AI Proteins, a biotech company pioneering a new class of de novo therapeutic miniproteins designed by artificial intelligence, today announced the appointment of Dr. James Bowman, PhD as its first Chief Technology Officer. In this role, James will drive the expansion of the company’s core technology platform, integrating machine learning, synthetic biology, robotics, and large-scale data analysis to create entirely novel protein therapeutics. He previously served as AI Proteins’ Director of Protein Engineering, where he helped establish the framework that powers the company’s discovery engine.

“Our vision is to bring miniprotein medicines to patients across many diseases. Accomplishing this requires industrializing the design-build-test process for drug discovery,” said Dr. Chris Bahl, CEO of AI Proteins. “James has been pivotal in building our protein engineering approach, and his promotion to CTO underscores both his contributions and our commitment to advancing the technology at the heart of AI Proteins.”

Before joining AI Proteins as a founding team member, James was a Postdoctoral Fellow at the Institute for Protein Innovation, Boston Children’s Hospital and Harvard Medical School, where he engineered novel miniproteins for cancer therapeutics, resulting in multiple patent applications and licenses.

"I'm incredibly excited to take on the role of CTO, and doubly thrilled to be leading our efforts to make our discovery engine even more amazing," said James Bowman. “We built a rapid, high-throughput approach for creating miniproteins with properties and functions that we pre-define and tailor to each project’s design goals. Miniproteins offer unique advantages over existing modalities, and our platform will allow this modality to reach its full potential in medicine.”

About AI Proteins

Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-enabled design and a high-throughput drug discovery platform, AI Proteins creates de novo miniproteins optimized for a variety of therapeutic applications. Partnered with leading biopharmaceutical companies, AI Proteins continues to pursue collaborations across a wide variety of therapeutic areas in addition to advancing its internal pipeline. The AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies.

For more information, please visit aiproteins.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250826782481/en/